organization · Reporting owner
FHM LIFE SCIENCES VIII, L.P.
Disclosed activity across 5 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALPINE IMMUNE SCIENCES, INC.ALPN · Entity 90802 | 10% owner | February 11, 2022 | February 15, 2022 |
| Sierra Oncology, Inc.SRRA · Entity 125698 | 10% owner | February 14, 2017 | February 24, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALPINE IMMUNE SCIENCES, INC.
Report date February 11, 2022 · Filed February 15, 2022
Jointly reported with Frazier Life Sciences VIII, L.P., FHM LIFE SCIENCES VIII, L.L.C., Heron Patrick J, Topper James N
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,484,115 |
Reported balance
After 2022-02-11 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2022-02-11 · Purchase · Acquired 112,665 · Balance 1,484,115 F1: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James N. Topper and Patrick J. Heron are the sole managing members of FHM LLC. Mr. Topper, Mr. Heron, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his or its pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James N. Topper and Patrick J. Heron are the sole managing members of FHM LLC. Mr. Topper, Mr. Heron, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his or its pecuniary interest therein, if any.
Sierra Oncology, Inc.
Report date February 14, 2017 · Filed February 24, 2017
Jointly reported with Frazier Healthcare VI, L.P., FHM VI, L.P., FHM VI, L.L.C., Frazier Life Sciences VIII, L.P., FHM LIFE SCIENCES VIII, L.L.C., FRAZIER ALAN D, Naini Nader J, Every Nathan R, Heron Patrick J
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,186,195 |
Reported balance
Holding disclosure · report date 2017-02-14 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 2,186,195 F1: Represents shares held by Frazier Healthcare VI, L.P., an affiliate of Frazier Healthcare Partners. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | Direct | 5,925,926 |
Reported balance
Holding disclosure · report date 2017-02-14 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 5,925,926 F2: Represents shares held by Frazier Life Sciences VIII, L.P., an affiliate of Frazier Healthcare Partners. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares held by Frazier Healthcare VI, L.P., an affiliate of Frazier Healthcare Partners. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any.
F2: Represents shares held by Frazier Life Sciences VIII, L.P., an affiliate of Frazier Healthcare Partners. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Aptinyx Inc.
Report date June 25, 2018 · Filed June 26, 2018
Jointly reported with Frazier Life Sciences VIII, L.P., FHM LIFE SCIENCES VIII, L.L.C., Heron Patrick J
Section 16 reporting ended · disclosed 2018-06-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,190,079 |
Last balance in matching sequence
After 2018-06-25 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
4 source rowsRow 1 · 2018-06-25 · Conversion · Acquired 1,047,450 · Balance 1,047,450 F1: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F2: The shares are held directly by Frazier Life Sciences VIII, L.P. ("FLS-VIII") and this report is filed jointly by Frazier Life Sciences VIII, L.P. ("FLS-VIII L.P."), FHM Life Sciences VIII, L.P. (FHM-VIII L.P."), FHM Life Sciences VIII, L.L.C. ("FHM-VIII LLC") and Patrick J. Heron. Shares are held directly by FLS-VIII. FHM-VIII L.P. serves as the sole general partner of FLS-VIII and owns no shares directly. FHM-VIII LLC serves as the sole general partner of FHM-VIII L.P. and owns no shares directly. Mr. Heron and James Topper are members of FHM-VIII LLC and share voting and dispositive power over the shares held by FLS-VIII; however, they disclaim beneficial ownership of the shares held by FLS-VIII except to the extent of their pecuniary interests therein. Row 2 · 2018-06-25 · Conversion · Acquired 1,197,076 · Balance 2,244,526 F1: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F2: The shares are held directly by Frazier Life Sciences VIII, L.P. ("FLS-VIII") and this report is filed jointly by Frazier Life Sciences VIII, L.P. ("FLS-VIII L.P."), FHM Life Sciences VIII, L.P. (FHM-VIII L.P."), FHM Life Sciences VIII, L.L.C. ("FHM-VIII LLC") and Patrick J. Heron. Shares are held directly by FLS-VIII. FHM-VIII L.P. serves as the sole general partner of FLS-VIII and owns no shares directly. FHM-VIII LLC serves as the sole general partner of FHM-VIII L.P. and owns no shares directly. Mr. Heron and James Topper are members of FHM-VIII LLC and share voting and dispositive power over the shares held by FLS-VIII; however, they disclaim beneficial ownership of the shares held by FLS-VIII except to the extent of their pecuniary interests therein. Row 3 · 2018-06-25 · Conversion · Acquired 795,553 · Balance 3,040,079 F1: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F2: The shares are held directly by Frazier Life Sciences VIII, L.P. ("FLS-VIII") and this report is filed jointly by Frazier Life Sciences VIII, L.P. ("FLS-VIII L.P."), FHM Life Sciences VIII, L.P. (FHM-VIII L.P."), FHM Life Sciences VIII, L.L.C. ("FHM-VIII LLC") and Patrick J. Heron. Shares are held directly by FLS-VIII. FHM-VIII L.P. serves as the sole general partner of FLS-VIII and owns no shares directly. FHM-VIII LLC serves as the sole general partner of FHM-VIII L.P. and owns no shares directly. Mr. Heron and James Topper are members of FHM-VIII LLC and share voting and dispositive power over the shares held by FLS-VIII; however, they disclaim beneficial ownership of the shares held by FLS-VIII except to the extent of their pecuniary interests therein. Row 4 · 2018-06-25 · Purchase · Acquired 150,000 · Balance 3,190,079 F3: On June 25, 2018, FLS-VIII purchased 150,000 shares of common stock of the Issuer at a price of $16.00 per share pursuant to an underwritten public offering. F2: The shares are held directly by Frazier Life Sciences VIII, L.P. ("FLS-VIII") and this report is filed jointly by Frazier Life Sciences VIII, L.P. ("FLS-VIII L.P."), FHM Life Sciences VIII, L.P. (FHM-VIII L.P."), FHM Life Sciences VIII, L.L.C. ("FHM-VIII LLC") and Patrick J. Heron. Shares are held directly by FLS-VIII. FHM-VIII L.P. serves as the sole general partner of FLS-VIII and owns no shares directly. FHM-VIII LLC serves as the sole general partner of FHM-VIII L.P. and owns no shares directly. Mr. Heron and James Topper are members of FHM-VIII LLC and share voting and dispositive power over the shares held by FLS-VIII; however, they disclaim beneficial ownership of the shares held by FLS-VIII except to the extent of their pecuniary interests therein. |
| Series A-1 Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2018-06-25 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-06-25 · Conversion · Disposed 28,895,188 · Balance 0 F1: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F2: The shares are held directly by Frazier Life Sciences VIII, L.P. ("FLS-VIII") and this report is filed jointly by Frazier Life Sciences VIII, L.P. ("FLS-VIII L.P."), FHM Life Sciences VIII, L.P. (FHM-VIII L.P."), FHM Life Sciences VIII, L.L.C. ("FHM-VIII LLC") and Patrick J. Heron. Shares are held directly by FLS-VIII. FHM-VIII L.P. serves as the sole general partner of FLS-VIII and owns no shares directly. FHM-VIII LLC serves as the sole general partner of FHM-VIII L.P. and owns no shares directly. Mr. Heron and James Topper are members of FHM-VIII LLC and share voting and dispositive power over the shares held by FLS-VIII; however, they disclaim beneficial ownership of the shares held by FLS-VIII except to the extent of their pecuniary interests therein. |
| Series A-2 Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2018-06-25 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-06-25 · Conversion · Disposed 33,022,786 · Balance 0 F1: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F2: The shares are held directly by Frazier Life Sciences VIII, L.P. ("FLS-VIII") and this report is filed jointly by Frazier Life Sciences VIII, L.P. ("FLS-VIII L.P."), FHM Life Sciences VIII, L.P. (FHM-VIII L.P."), FHM Life Sciences VIII, L.L.C. ("FHM-VIII LLC") and Patrick J. Heron. Shares are held directly by FLS-VIII. FHM-VIII L.P. serves as the sole general partner of FLS-VIII and owns no shares directly. FHM-VIII LLC serves as the sole general partner of FHM-VIII L.P. and owns no shares directly. Mr. Heron and James Topper are members of FHM-VIII LLC and share voting and dispositive power over the shares held by FLS-VIII; however, they disclaim beneficial ownership of the shares held by FLS-VIII except to the extent of their pecuniary interests therein. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2018-06-25 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-06-25 · Conversion · Disposed 21,946,301 · Balance 0 F1: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F2: The shares are held directly by Frazier Life Sciences VIII, L.P. ("FLS-VIII") and this report is filed jointly by Frazier Life Sciences VIII, L.P. ("FLS-VIII L.P."), FHM Life Sciences VIII, L.P. (FHM-VIII L.P."), FHM Life Sciences VIII, L.L.C. ("FHM-VIII LLC") and Patrick J. Heron. Shares are held directly by FLS-VIII. FHM-VIII L.P. serves as the sole general partner of FLS-VIII and owns no shares directly. FHM-VIII LLC serves as the sole general partner of FHM-VIII L.P. and owns no shares directly. Mr. Heron and James Topper are members of FHM-VIII LLC and share voting and dispositive power over the shares held by FLS-VIII; however, they disclaim beneficial ownership of the shares held by FLS-VIII except to the extent of their pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date.
F2: The shares are held directly by Frazier Life Sciences VIII, L.P. ("FLS-VIII") and this report is filed jointly by Frazier Life Sciences VIII, L.P. ("FLS-VIII L.P."), FHM Life Sciences VIII, L.P. (FHM-VIII L.P."), FHM Life Sciences VIII, L.L.C. ("FHM-VIII LLC") and Patrick J. Heron. Shares are held directly by FLS-VIII. FHM-VIII L.P. serves as the sole general partner of FLS-VIII and owns no shares directly. FHM-VIII LLC serves as the sole general partner of FHM-VIII L.P. and owns no shares directly. Mr. Heron and James Topper are members of FHM-VIII LLC and share voting and dispositive power over the shares held by FLS-VIII; however, they disclaim beneficial ownership of the shares held by FLS-VIII except to the extent of their pecuniary interests therein.
F3: On June 25, 2018, FLS-VIII purchased 150,000 shares of common stock of the Issuer at a price of $16.00 per share pursuant to an underwritten public offering.
Arcutis Biotherapeutics, Inc.
Report date October 24, 2023 · Filed October 26, 2023
Jointly reported with Frazier Life Sciences VIII, L.P., FHM LIFE SCIENCES VIII, L.L.C., Topper James N, Heron Patrick J
Section 16 reporting ended · disclosed 2023-10-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,764,232 |
Reported balance
After 2023-10-24 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2023-10-24 · Purchase · Acquired 80,000 · Balance 8,764,232 |
| Common StockSEC Table I · non-derivative | IndirectFHM Life Sciences VIII, L.L.C. | 7 |
Reported balance
Holding disclosure · report date 2023-10-24 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 7 F1: Represents shares held of record by FHM Life Sciences VIII, L.L.C. Dr. Topper and Mr. Heron are the sole managing members of FHM Life Sciences VIII, L.L.C. and share voting and investment power of the securities held by FHM Life Sciences VIII, L.L.C. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Topper Group II LLC | 11,266 |
Reported balance
Holding disclosure · report date 2023-10-24 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 11,266 F2: Dr. Topper is a manager of Topper Group II LLC and shares voting and investment power over the shares held by Topper Group II LLC. |
| Common StockSEC Table I · non-derivative | IndirectBy Topper Family Revocable Trust | 19,381 |
Reported balance
Holding disclosure · report date 2023-10-24 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 19,381 F3: Dr. Topper is a trustee of the Topper Family Revocable Trust and has voting and investment power over the shares held by Topper Family Revocable Trust. |
| Common StockSEC Table I · non-derivative | IndirectBy The Heron Living Trust 11/30/2004 | 23,688 |
Reported balance
Holding disclosure · report date 2023-10-24 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 23,688 F4: Mr. Heron is the co-trustee of The Heron Living Trust 11/30/2004 and has voting and investment power of the securities held by The Heron Living Trust 11/30/2004. |
| Common StockSEC Table I · non-derivative | IndirectBy Patrick J. Heron | 8,687 |
Reported balance
Holding disclosure · report date 2023-10-24 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 8,687 F5: Includes 4,375 Restricted Stock Units ("RSUs"). Mr. Heron is entitled to receive one (1) share of the Issuer's Common Stock for each one (1) RSU upon the vesting thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares held of record by FHM Life Sciences VIII, L.L.C. Dr. Topper and Mr. Heron are the sole managing members of FHM Life Sciences VIII, L.L.C. and share voting and investment power of the securities held by FHM Life Sciences VIII, L.L.C. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
F2: Dr. Topper is a manager of Topper Group II LLC and shares voting and investment power over the shares held by Topper Group II LLC.
F3: Dr. Topper is a trustee of the Topper Family Revocable Trust and has voting and investment power over the shares held by Topper Family Revocable Trust.
F4: Mr. Heron is the co-trustee of The Heron Living Trust 11/30/2004 and has voting and investment power of the securities held by The Heron Living Trust 11/30/2004.
F5: Includes 4,375 Restricted Stock Units ("RSUs"). Mr. Heron is entitled to receive one (1) share of the Issuer's Common Stock for each one (1) RSU upon the vesting thereof.
Entasis Therapeutics Holdings Inc.
Report date January 09, 2020 · Filed January 13, 2020
Jointly reported with Frazier Life Sciences VIII, L.P., Topper James N, FHM LIFE SCIENCES VIII, L.L.C., Heron Patrick J
Section 16 reporting ended · disclosed 2020-01-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,299,953 |
Reported balance
After 2020-01-09 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2020-01-09 · Sale · Disposed 50,000 · Balance 1,299,953 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.00 to $5.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 1 to this Form 4 F2: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Heron, Mr. Topper, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his or its pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.00 to $5.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 1 to this Form 4
F2: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Heron, Mr. Topper, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his or its pecuniary interest therein, if any.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 24, 2023 Filed Oct 26, 2023 20:09 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | PurchaseCommon Stock | 80,000 | $2.50 | $200,000.00 |
DisclosureSEC source: 0001209191-23-053662 · doc4.xml · nonDerivative · entry 1 Frazier Life Sciences VIII, L.P. · CIK 0001655827 · 10% owner FHM LIFE SCIENCES VIII, L.P. · CIK 0001698755 · 10% owner FHM LIFE SCIENCES VIII, L.L.C. · CIK 0001698823 · 10% owner Topper James N · CIK 0001341382 · 10% owner Heron Patrick J · CIK 0001365617 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,764,232 Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 20:34 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | PurchaseCommon Stock | 250,000 | $20.00 | $5,000,000.00 |
DisclosureSEC source: 0001209191-22-045014 · doc4.xml · nonDerivative · entry 1 Frazier Life Sciences VIII, L.P. · CIK 0001655827 · 10% owner FHM LIFE SCIENCES VIII, L.P. · CIK 0001698755 · 10% owner FHM LIFE SCIENCES VIII, L.L.C. · CIK 0001698823 · 10% owner Topper James N · CIK 0001341382 · 10% owner Heron Patrick J · CIK 0001365617 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,684,232 Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 22:00 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | PurchaseCommon Stock | 112,665 | $7.10 | $799,989.10 |
DisclosureSEC source: 0001209191-22-009821 · doc4.xml · nonDerivative · entry 1 Frazier Life Sciences VIII, L.P. · CIK 0001655827 · 10% owner FHM LIFE SCIENCES VIII, L.P. · CIK 0001698755 · 10% owner FHM LIFE SCIENCES VIII, L.L.C. · CIK 0001698823 · 10% owner Heron Patrick J · CIK 0001365617 · 10% owner Topper James N · CIK 0001341382 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,484,115 F1 · ownership.direct: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James N. Topper and Patrick J. Heron are the sole managing members of FHM LLC. Mr. Topper, Mr. Heron, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| September 17, 2021 Filed Sep 21, 2021 17:54 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | GrantWarrant (Right to Buy) · Derivative | 1,200,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-057010 · doc4.xml · derivative · entry 2 Frazier Life Sciences VIII, L.P. · CIK 0001655827 · 10% owner FHM LIFE SCIENCES VIII, L.L.C. · CIK 0001698823 · 10% owner Heron Patrick J · CIK 0001365617 · 10% owner Topper James N · CIK 0001341382 · Director · 10% owner FHM LIFE SCIENCES VIII, L.P. · CIK 0001698755 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,200,000 Underlying: Common Stock · 1,200,000 shares Expires not disclosed F3 · derivative.exercise_date: The Pre-Funded Warrant has no expiration date and is exercisable immediately. Notwithstanding the foregoing, the Reporting Person shall not be entitled to exercise the Pre-Funded Warrant if it would cause (i) the aggregate number of shares of Common Stock beneficially owned by the Reporting Person, its affiliates and any persons who are members of a Section 13(d) group with the Reporting Person or its affiliates to exceed 9.99% (the "Maximum Percentage") of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise, or (ii) the combined voting power of the securities of the Issuer beneficially owned by the Reporting Person and its affiliates and any other persons who are members of a Section 13(d) group with the Reporting Person or its affiliates to exceed the Maximum Percentage of the combined voting power of all of the securities of the Issuer then outstanding following such exercise. F4 · derivative.exercise_date: The Maximum Percentage can be changed by the holder upon 61 days notice to the Issuer. F3 · derivative.expiration_date: The Pre-Funded Warrant has no expiration date and is exercisable immediately. Notwithstanding the foregoing, the Reporting Person shall not be entitled to exercise the Pre-Funded Warrant if it would cause (i) the aggregate number of shares of Common Stock beneficially owned by the Reporting Person, its affiliates and any persons who are members of a Section 13(d) group with the Reporting Person or its affiliates to exceed 9.99% (the "Maximum Percentage") of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise, or (ii) the combined voting power of the securities of the Issuer beneficially owned by the Reporting Person and its affiliates and any other persons who are members of a Section 13(d) group with the Reporting Person or its affiliates to exceed the Maximum Percentage of the combined voting power of all of the securities of the Issuer then outstanding following such exercise. F4 · derivative.expiration_date: The Maximum Percentage can be changed by the holder upon 61 days notice to the Issuer. F2 · ownership.direct: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James N. Topper and Patrick J. Heron are the sole managing members of FHM LLC. Mr. Topper, Mr. Heron, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| September 17, 2021 Filed Sep 21, 2021 17:54 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Disposition to issuerCommon Stock | 1,200,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-057010 · doc4.xml · nonDerivative · entry 1 Frazier Life Sciences VIII, L.P. · CIK 0001655827 · 10% owner FHM LIFE SCIENCES VIII, L.L.C. · CIK 0001698823 · 10% owner Heron Patrick J · CIK 0001365617 · 10% owner Topper James N · CIK 0001341382 · Director · 10% owner FHM LIFE SCIENCES VIII, L.P. · CIK 0001698755 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,371,450 F1 · price: Frazier Life Sciences VIII, L.P. entered into an Exchange Agreement with the Issuer pursuant to which, Frazier Life Sciences VIII, L.P. exchanged, on a 1:1 basis, 1,200,000 shares of the Issuer's Common Stock for a prefunded warrant to purchase 1,200,000 shares of the Issuer's Common Stock at an exercise price of $0.001 per share (the "Pre-Funded Warrant"). F2 · ownership.direct: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James N. Topper and Patrick J. Heron are the sole managing members of FHM LLC. Mr. Topper, Mr. Heron, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| May 10, 2021 Filed May 12, 2021 21:37 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | OtherCommon Stock | 96,574 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-032151 · doc4.xml · nonDerivative · entry 3 Frazier Life Sciences VIII, L.P. · CIK 0001655827 · 10% owner FHM LIFE SCIENCES VIII, L.L.C. · CIK 0001698823 · 10% owner Heron Patrick J · CIK 0001365617 · Director · 10% owner Topper James N · CIK 0001341382 · 10% owner FHM LIFE SCIENCES VIII, L.P. · CIK 0001698755 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By FHM Life Sciences VIII, L.P. Disclosed balance after: 0 F5 · kind: Represents a pro rata in-kind stock distribution by FHM Life Sciences VIII, L.P. to its limited partners for no consideration. F4 · ownership.nature: Represents shares held of record by FHM Life Sciences VIII, L.P. The general partner of FHM Life Sciences VIII, L.P. is FHM Life Sciences VIII, L.L.C. Dr. Topper and Dr. Heron are the sole managing members of FHM Life Sciences VIII, L.L.C. and share voting and investment power of the securities held by FHM Life Sciences VIII, L.P. Dr. Topper and Dr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document |
| May 10, 2021 Filed May 12, 2021 21:37 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | OtherCommon Stock | 96,574 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-032151 · doc4.xml · nonDerivative · entry 2 Frazier Life Sciences VIII, L.P. · CIK 0001655827 · 10% owner FHM LIFE SCIENCES VIII, L.L.C. · CIK 0001698823 · 10% owner Heron Patrick J · CIK 0001365617 · Director · 10% owner Topper James N · CIK 0001341382 · 10% owner FHM LIFE SCIENCES VIII, L.P. · CIK 0001698755 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By FHM Life Sciences VIII, L.P. Disclosed balance after: 96,574 F3 · kind: Reflects shares of Common Stock received from FLS VIII in the in-kind stock distribution described herein. F4 · ownership.nature: Represents shares held of record by FHM Life Sciences VIII, L.P. The general partner of FHM Life Sciences VIII, L.P. is FHM Life Sciences VIII, L.L.C. Dr. Topper and Dr. Heron are the sole managing members of FHM Life Sciences VIII, L.L.C. and share voting and investment power of the securities held by FHM Life Sciences VIII, L.P. Dr. Topper and Dr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document |
| May 10, 2021 Filed May 12, 2021 21:37 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | OtherCommon Stock | 2,108,558 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-032151 · doc4.xml · nonDerivative · entry 1 Frazier Life Sciences VIII, L.P. · CIK 0001655827 · 10% owner FHM LIFE SCIENCES VIII, L.L.C. · CIK 0001698823 · 10% owner Heron Patrick J · CIK 0001365617 · Director · 10% owner Topper James N · CIK 0001341382 · 10% owner FHM LIFE SCIENCES VIII, L.P. · CIK 0001698755 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,434,232 F1 · kind: Represents a pro rata in-kind stock distribution by Frazier Life Sciences VIII, L.P. ("FLS VIII") to its limited partners and general partner for no consideration. F2 · ownership.direct: Represents shares held of record by FLS VIII. The general partner of FLS VIII is FHM Life Sciences VIII, L.P., and the general partner of FHM Life Sciences VIII, L.P. is FHM Life Sciences VIII, L.L.C. James Topper and Patrick Heron are the sole managing members of FHM Life Sciences VIII, L.L.C. and share voting and investment power of the securities held by FLS VIII. Dr. Topper and Dr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 15:29 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | ConversionSeries C Preferred Stock · Derivative | 1,074,467 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007100 · doc4.xml · derivative · entry 7 Frazier Life Sciences VIII, L.P. · CIK 0001655827 · 10% owner FHM LIFE SCIENCES VIII, L.P. · CIK 0001698755 · 10% owner FHM LIFE SCIENCES VIII, L.L.C. · CIK 0001698823 · 10% owner Topper James N · CIK 0001341382 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,074,467 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering. F2 · ownership.direct: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Topper, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP, except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 15:29 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | ConversionSeries B Preferred Stock · Derivative | 2,099,019 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007100 · doc4.xml · derivative · entry 6 Frazier Life Sciences VIII, L.P. · CIK 0001655827 · 10% owner FHM LIFE SCIENCES VIII, L.P. · CIK 0001698755 · 10% owner FHM LIFE SCIENCES VIII, L.L.C. · CIK 0001698823 · 10% owner Topper James N · CIK 0001341382 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,099,019 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering. F2 · ownership.direct: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Topper, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP, except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 15:29 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | ConversionSeries A Preferred Stock · Derivative | 6,360,272 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007100 · doc4.xml · derivative · entry 5 Frazier Life Sciences VIII, L.P. · CIK 0001655827 · 10% owner FHM LIFE SCIENCES VIII, L.P. · CIK 0001698755 · 10% owner FHM LIFE SCIENCES VIII, L.L.C. · CIK 0001698823 · 10% owner Topper James N · CIK 0001341382 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,360,272 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering. F2 · ownership.direct: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Topper, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP, except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 15:29 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | PurchaseCommon Stock | 500,000 | $17.00 | $8,500,000.00 |
DisclosureSEC source: 0001209191-20-007100 · doc4.xml · nonDerivative · entry 4 Frazier Life Sciences VIII, L.P. · CIK 0001655827 · 10% owner FHM LIFE SCIENCES VIII, L.P. · CIK 0001698755 · 10% owner FHM LIFE SCIENCES VIII, L.L.C. · CIK 0001698823 · 10% owner Topper James N · CIK 0001341382 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,542,790 F2 · ownership.direct: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Topper, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP, except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 15:29 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | ConversionCommon Stock | 1,074,467 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-007100 · doc4.xml · nonDerivative · entry 3 Frazier Life Sciences VIII, L.P. · CIK 0001655827 · 10% owner FHM LIFE SCIENCES VIII, L.P. · CIK 0001698755 · 10% owner FHM LIFE SCIENCES VIII, L.L.C. · CIK 0001698823 · 10% owner Topper James N · CIK 0001341382 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,042,790 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering. F2 · ownership.direct: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Topper, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP, except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 15:29 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | ConversionCommon Stock | 2,099,019 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-007100 · doc4.xml · nonDerivative · entry 2 Frazier Life Sciences VIII, L.P. · CIK 0001655827 · 10% owner FHM LIFE SCIENCES VIII, L.P. · CIK 0001698755 · 10% owner FHM LIFE SCIENCES VIII, L.L.C. · CIK 0001698823 · 10% owner Topper James N · CIK 0001341382 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,968,323 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering. F2 · ownership.direct: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Topper, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP, except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 15:29 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | ConversionCommon Stock | 6,360,272 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-007100 · doc4.xml · nonDerivative · entry 1 Frazier Life Sciences VIII, L.P. · CIK 0001655827 · 10% owner FHM LIFE SCIENCES VIII, L.P. · CIK 0001698755 · 10% owner FHM LIFE SCIENCES VIII, L.L.C. · CIK 0001698823 · 10% owner Topper James N · CIK 0001341382 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,869,304 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering. F2 · ownership.direct: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Topper, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP, except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| January 09, 2020 Filed Jan 13, 2020 15:47 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | SaleCommon Stock | 50,000 | $5.00 | $250,010.00 |
DisclosureSEC source: 0001209191-20-003162 · doc4.xml · nonDerivative · entry 1 Frazier Life Sciences VIII, L.P. · CIK 0001655827 · 10% owner Topper James N · CIK 0001341382 · 10% owner FHM LIFE SCIENCES VIII, L.P. · CIK 0001698755 · 10% owner FHM LIFE SCIENCES VIII, L.L.C. · CIK 0001698823 · 10% owner Heron Patrick J · CIK 0001365617 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,299,953 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.00 to $5.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 1 to this Form 4 F2 · ownership.direct: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Heron, Mr. Topper, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| January 18, 2019 Filed Jan 22, 2019 22:14 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | PurchaseWarrant (Right to Buy) · Derivative | 145,251 | $0.00 Strike: $12.74 | $0.00 |
DisclosureSEC source: 0001209191-19-004783 · doc4.xml · derivative · entry 2 Frazier Life Sciences VIII, L.P. · CIK 0001655827 · 10% owner FHM LIFE SCIENCES VIII, L.P. · CIK 0001698755 · 10% owner FHM LIFE SCIENCES VIII, L.L.C. · CIK 0001698823 · 10% owner Heron Patrick J · CIK 0001365617 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,251 Underlying: Common Stock · 145,251 shares Expires 2024-01-18 F1 · ownership.direct: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Heron, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| January 18, 2019 Filed Jan 22, 2019 22:14 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | PurchaseCommon Stock | 372,439 | $5.37 | $1,999,997.43 |
DisclosureSEC source: 0001209191-19-004783 · doc4.xml · nonDerivative · entry 1 Frazier Life Sciences VIII, L.P. · CIK 0001655827 · 10% owner FHM LIFE SCIENCES VIII, L.P. · CIK 0001698755 · 10% owner FHM LIFE SCIENCES VIII, L.L.C. · CIK 0001698823 · 10% owner Heron Patrick J · CIK 0001365617 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,571,450 F1 · ownership.direct: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Heron, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| September 28, 2018 Filed Oct 3, 2018 01:38 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | ConversionSeries B-1 Tranche B Convertible Preferred Stock · Derivative | 6,651,574 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-053535 · doc4.xml · derivative · entry 7 Frazier Life Sciences VIII, L.P. · CIK 0001655827 · 10% owner FHM LIFE SCIENCES VIII, L.L.C. · CIK 0001698823 · 10% owner Heron Patrick J · CIK 0001365617 · 10% owner FHM LIFE SCIENCES VIII, L.P. · CIK 0001698755 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 320,898 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.underlying_shares: Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.direct: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Heron, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| September 28, 2018 Filed Oct 3, 2018 01:38 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | ConversionSeries B-1 Tranche A Convertible Preferred Stock · Derivative | 5,212,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-053535 · doc4.xml · derivative · entry 6 Frazier Life Sciences VIII, L.P. · CIK 0001655827 · 10% owner FHM LIFE SCIENCES VIII, L.L.C. · CIK 0001698823 · 10% owner Heron Patrick J · CIK 0001365617 · 10% owner FHM LIFE SCIENCES VIII, L.P. · CIK 0001698755 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 251,487 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.underlying_shares: Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.direct: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Heron, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| September 28, 2018 Filed Oct 3, 2018 01:38 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | ConversionSeries B Convertible Preferred Stock · Derivative | 7,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-053535 · doc4.xml · derivative · entry 5 Frazier Life Sciences VIII, L.P. · CIK 0001655827 · 10% owner FHM LIFE SCIENCES VIII, L.L.C. · CIK 0001698823 · 10% owner Heron Patrick J · CIK 0001365617 · 10% owner FHM LIFE SCIENCES VIII, L.P. · CIK 0001698755 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 337,707 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.underlying_shares: Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.direct: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Heron, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| September 28, 2018 Filed Oct 3, 2018 01:38 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | PurchaseCommon Stock | 375,887 | $15.00 | $5,638,305.00 |
DisclosureSEC source: 0001209191-18-053535 · doc4.xml · nonDerivative · entry 4 Frazier Life Sciences VIII, L.P. · CIK 0001655827 · 10% owner FHM LIFE SCIENCES VIII, L.L.C. · CIK 0001698823 · 10% owner Heron Patrick J · CIK 0001365617 · 10% owner FHM LIFE SCIENCES VIII, L.P. · CIK 0001698755 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,349,953 F2 · ownership.direct: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Heron, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| September 28, 2018 Filed Oct 3, 2018 01:38 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | ConversionCommon Stock | 320,898 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-053535 · doc4.xml · nonDerivative · entry 3 Frazier Life Sciences VIII, L.P. · CIK 0001655827 · 10% owner FHM LIFE SCIENCES VIII, L.L.C. · CIK 0001698823 · 10% owner Heron Patrick J · CIK 0001365617 · 10% owner FHM LIFE SCIENCES VIII, L.P. · CIK 0001698755 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 974,066 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F3 · balance_after: This number includes an aggregate of 63,974 shares of Common Stock received upon the conversion of the Issuer's Preferred Stock as payment of the accrued dividends through September 27, 2018. No dividends will accrue after September 27, 2018. F2 · ownership.direct: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Heron, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| September 28, 2018 Filed Oct 3, 2018 01:38 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | ConversionCommon Stock | 251,487 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-053535 · doc4.xml · nonDerivative · entry 2 Frazier Life Sciences VIII, L.P. · CIK 0001655827 · 10% owner FHM LIFE SCIENCES VIII, L.L.C. · CIK 0001698823 · 10% owner Heron Patrick J · CIK 0001365617 · 10% owner FHM LIFE SCIENCES VIII, L.P. · CIK 0001698755 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 589,194 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.direct: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Heron, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| September 28, 2018 Filed Oct 3, 2018 01:38 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | ConversionCommon Stock | 337,707 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-053535 · doc4.xml · nonDerivative · entry 1 Frazier Life Sciences VIII, L.P. · CIK 0001655827 · 10% owner FHM LIFE SCIENCES VIII, L.L.C. · CIK 0001698823 · 10% owner Heron Patrick J · CIK 0001365617 · 10% owner FHM LIFE SCIENCES VIII, L.P. · CIK 0001698755 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,707 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.direct: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Heron, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| June 25, 2018 Filed Jun 26, 2018 16:56 UTC | Aptinyx Inc. APTX · Entity 120922 | ConversionSeries B Convertible Preferred Stock · Derivative | 21,946,301 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-042315 · a4.xml · derivative · entry 7 Frazier Life Sciences VIII, L.P. · CIK 0001655827 · 10% owner FHM LIFE SCIENCES VIII, L.P. · CIK 0001698755 · 10% owner FHM LIFE SCIENCES VIII, L.L.C. · CIK 0001698823 · 10% owner Heron Patrick J · CIK 0001365617 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 795,553 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · date: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · price: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F2 · ownership.nature: The shares are held directly by Frazier Life Sciences VIII, L.P. ("FLS-VIII") and this report is filed jointly by Frazier Life Sciences VIII, L.P. ("FLS-VIII L.P."), FHM Life Sciences VIII, L.P. (FHM-VIII L.P."), FHM Life Sciences VIII, L.L.C. ("FHM-VIII LLC") and Patrick J. Heron. Shares are held directly by FLS-VIII. FHM-VIII L.P. serves as the sole general partner of FLS-VIII and owns no shares directly. FHM-VIII LLC serves as the sole general partner of FHM-VIII L.P. and owns no shares directly. Mr. Heron and James Topper are members of FHM-VIII LLC and share voting and dispositive power over the shares held by FLS-VIII; however, they disclaim beneficial ownership of the shares held by FLS-VIII except to the extent of their pecuniary interests therein. Read SEC document |
| June 25, 2018 Filed Jun 26, 2018 16:56 UTC | Aptinyx Inc. APTX · Entity 120922 | ConversionSeries A-2 Convertible Preferred Stock · Derivative | 33,022,786 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-042315 · a4.xml · derivative · entry 6 Frazier Life Sciences VIII, L.P. · CIK 0001655827 · 10% owner FHM LIFE SCIENCES VIII, L.P. · CIK 0001698755 · 10% owner FHM LIFE SCIENCES VIII, L.L.C. · CIK 0001698823 · 10% owner Heron Patrick J · CIK 0001365617 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,197,076 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · date: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · price: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F2 · ownership.nature: The shares are held directly by Frazier Life Sciences VIII, L.P. ("FLS-VIII") and this report is filed jointly by Frazier Life Sciences VIII, L.P. ("FLS-VIII L.P."), FHM Life Sciences VIII, L.P. (FHM-VIII L.P."), FHM Life Sciences VIII, L.L.C. ("FHM-VIII LLC") and Patrick J. Heron. Shares are held directly by FLS-VIII. FHM-VIII L.P. serves as the sole general partner of FLS-VIII and owns no shares directly. FHM-VIII LLC serves as the sole general partner of FHM-VIII L.P. and owns no shares directly. Mr. Heron and James Topper are members of FHM-VIII LLC and share voting and dispositive power over the shares held by FLS-VIII; however, they disclaim beneficial ownership of the shares held by FLS-VIII except to the extent of their pecuniary interests therein. Read SEC document |
| June 25, 2018 Filed Jun 26, 2018 16:56 UTC | Aptinyx Inc. APTX · Entity 120922 | ConversionSeries A-1 Convertible Preferred Stock · Derivative | 28,895,188 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-042315 · a4.xml · derivative · entry 5 Frazier Life Sciences VIII, L.P. · CIK 0001655827 · 10% owner FHM LIFE SCIENCES VIII, L.P. · CIK 0001698755 · 10% owner FHM LIFE SCIENCES VIII, L.L.C. · CIK 0001698823 · 10% owner Heron Patrick J · CIK 0001365617 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,047,450 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · date: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · price: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F2 · ownership.nature: The shares are held directly by Frazier Life Sciences VIII, L.P. ("FLS-VIII") and this report is filed jointly by Frazier Life Sciences VIII, L.P. ("FLS-VIII L.P."), FHM Life Sciences VIII, L.P. (FHM-VIII L.P."), FHM Life Sciences VIII, L.L.C. ("FHM-VIII LLC") and Patrick J. Heron. Shares are held directly by FLS-VIII. FHM-VIII L.P. serves as the sole general partner of FLS-VIII and owns no shares directly. FHM-VIII LLC serves as the sole general partner of FHM-VIII L.P. and owns no shares directly. Mr. Heron and James Topper are members of FHM-VIII LLC and share voting and dispositive power over the shares held by FLS-VIII; however, they disclaim beneficial ownership of the shares held by FLS-VIII except to the extent of their pecuniary interests therein. Read SEC document |
| June 25, 2018 Filed Jun 26, 2018 16:56 UTC | Aptinyx Inc. APTX · Entity 120922 | PurchaseCommon Stock | 150,000 | $16.00 | $2,400,000.00 |
DisclosureSEC source: 0001104659-18-042315 · a4.xml · nonDerivative · entry 4 Frazier Life Sciences VIII, L.P. · CIK 0001655827 · 10% owner FHM LIFE SCIENCES VIII, L.P. · CIK 0001698755 · 10% owner FHM LIFE SCIENCES VIII, L.L.C. · CIK 0001698823 · 10% owner Heron Patrick J · CIK 0001365617 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,190,079 F3 · shares: On June 25, 2018, FLS-VIII purchased 150,000 shares of common stock of the Issuer at a price of $16.00 per share pursuant to an underwritten public offering. F2 · ownership.direct: The shares are held directly by Frazier Life Sciences VIII, L.P. ("FLS-VIII") and this report is filed jointly by Frazier Life Sciences VIII, L.P. ("FLS-VIII L.P."), FHM Life Sciences VIII, L.P. (FHM-VIII L.P."), FHM Life Sciences VIII, L.L.C. ("FHM-VIII LLC") and Patrick J. Heron. Shares are held directly by FLS-VIII. FHM-VIII L.P. serves as the sole general partner of FLS-VIII and owns no shares directly. FHM-VIII LLC serves as the sole general partner of FHM-VIII L.P. and owns no shares directly. Mr. Heron and James Topper are members of FHM-VIII LLC and share voting and dispositive power over the shares held by FLS-VIII; however, they disclaim beneficial ownership of the shares held by FLS-VIII except to the extent of their pecuniary interests therein. Read SEC document |
| June 25, 2018 Filed Jun 26, 2018 16:56 UTC | Aptinyx Inc. APTX · Entity 120922 | ConversionCommon Stock | 795,553 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-042315 · a4.xml · nonDerivative · entry 3 Frazier Life Sciences VIII, L.P. · CIK 0001655827 · 10% owner FHM LIFE SCIENCES VIII, L.P. · CIK 0001698755 · 10% owner FHM LIFE SCIENCES VIII, L.L.C. · CIK 0001698823 · 10% owner Heron Patrick J · CIK 0001365617 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,040,079 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · price: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F2 · ownership.direct: The shares are held directly by Frazier Life Sciences VIII, L.P. ("FLS-VIII") and this report is filed jointly by Frazier Life Sciences VIII, L.P. ("FLS-VIII L.P."), FHM Life Sciences VIII, L.P. (FHM-VIII L.P."), FHM Life Sciences VIII, L.L.C. ("FHM-VIII LLC") and Patrick J. Heron. Shares are held directly by FLS-VIII. FHM-VIII L.P. serves as the sole general partner of FLS-VIII and owns no shares directly. FHM-VIII LLC serves as the sole general partner of FHM-VIII L.P. and owns no shares directly. Mr. Heron and James Topper are members of FHM-VIII LLC and share voting and dispositive power over the shares held by FLS-VIII; however, they disclaim beneficial ownership of the shares held by FLS-VIII except to the extent of their pecuniary interests therein. Read SEC document |
| June 25, 2018 Filed Jun 26, 2018 16:56 UTC | Aptinyx Inc. APTX · Entity 120922 | ConversionCommon Stock | 1,197,076 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-042315 · a4.xml · nonDerivative · entry 2 Frazier Life Sciences VIII, L.P. · CIK 0001655827 · 10% owner FHM LIFE SCIENCES VIII, L.P. · CIK 0001698755 · 10% owner FHM LIFE SCIENCES VIII, L.L.C. · CIK 0001698823 · 10% owner Heron Patrick J · CIK 0001365617 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,244,526 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · price: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F2 · ownership.direct: The shares are held directly by Frazier Life Sciences VIII, L.P. ("FLS-VIII") and this report is filed jointly by Frazier Life Sciences VIII, L.P. ("FLS-VIII L.P."), FHM Life Sciences VIII, L.P. (FHM-VIII L.P."), FHM Life Sciences VIII, L.L.C. ("FHM-VIII LLC") and Patrick J. Heron. Shares are held directly by FLS-VIII. FHM-VIII L.P. serves as the sole general partner of FLS-VIII and owns no shares directly. FHM-VIII LLC serves as the sole general partner of FHM-VIII L.P. and owns no shares directly. Mr. Heron and James Topper are members of FHM-VIII LLC and share voting and dispositive power over the shares held by FLS-VIII; however, they disclaim beneficial ownership of the shares held by FLS-VIII except to the extent of their pecuniary interests therein. Read SEC document |
| June 25, 2018 Filed Jun 26, 2018 16:56 UTC | Aptinyx Inc. APTX · Entity 120922 | ConversionCommon Stock | 1,047,450 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-042315 · a4.xml · nonDerivative · entry 1 Frazier Life Sciences VIII, L.P. · CIK 0001655827 · 10% owner FHM LIFE SCIENCES VIII, L.P. · CIK 0001698755 · 10% owner FHM LIFE SCIENCES VIII, L.L.C. · CIK 0001698823 · 10% owner Heron Patrick J · CIK 0001365617 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,047,450 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · price: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F2 · ownership.direct: The shares are held directly by Frazier Life Sciences VIII, L.P. ("FLS-VIII") and this report is filed jointly by Frazier Life Sciences VIII, L.P. ("FLS-VIII L.P."), FHM Life Sciences VIII, L.P. (FHM-VIII L.P."), FHM Life Sciences VIII, L.L.C. ("FHM-VIII LLC") and Patrick J. Heron. Shares are held directly by FLS-VIII. FHM-VIII L.P. serves as the sole general partner of FLS-VIII and owns no shares directly. FHM-VIII LLC serves as the sole general partner of FHM-VIII L.P. and owns no shares directly. Mr. Heron and James Topper are members of FHM-VIII LLC and share voting and dispositive power over the shares held by FLS-VIII; however, they disclaim beneficial ownership of the shares held by FLS-VIII except to the extent of their pecuniary interests therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.